A major step forward in evaluating potential drugs for schizophrenia
A major step forward in evaluating potential drugs for schizophrenia
PsyRING offers a unique well established and validated model of schizophrenia.
The model is able to evaluate efficacy of potential drugs alone or compared against clozapine.
It offers major advantages compared to exisiting models. It is the only model to reproduce hypofrontality and cognitive deficits and has the ability to detect compounds that are predicted to treat the negative symptoms and cognitive deficits of schizophrenia:
This is the only model to reproduce all these core features.
The negative symptoms and cognitive deficits of schizophrenia are the symptoms that present the major barrier to long-term recovery of patients, and are poorly treated by existing drugs.
Notably, proof of concept data on a novel drug target in an earlier work programme has revealed improved ability to reverse these deficits over clozapine. Thus this model has the ability to detect compounds that would be predicted to have a superior action to clozapine for the treatment of schizophrenia.